Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models

por Tohyama, Osamu, Matsui, Junji, Kodama, Kotaro, Hata-Sugi, Naoko, Kimura, Takayuki, Okamoto, Kiyoshi, Minoshima, Yukinori, Iwata, Masao, Funahashi, Yasuhiro
Publicado 2014

Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model

por Kimura, Takayuki, Kato, Yu, Ozawa, Yoichi, Kodama, Kotaro, Ito, Junichi, Ichikawa, Kenji, Yamada, Kazuhiko, Hori, Yusaku, Tabata, Kimiyo, Takase, Kazuma, Matsui, Junji, Funahashi, Yasuhiro, Nomoto, Kenichi
Publicado 2018

Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies

por Adachi, Yusuke, Kamiyama, Hiroshi, Ichikawa, Kenji, Fukushima, Sayo, Ozawa, Yoichi, Yamaguchi, Shogo, Goda, Satoshi, Kimura, Takayuki, Kodama, Kotaro, Matsuki, Masahiro, Miyano, Saori Watanabe, Yokoi, Akira, Kato, Yu, Funahashi, Yasuhiro
Publicado 2022